Long-acting PrEP: new opportunities with some drawbacks
- PMID: 36642088
- DOI: 10.1016/S2352-3018(22)00397-6
Long-acting PrEP: new opportunities with some drawbacks
Conflict of interest statement
MX declares no competing interests. EH obtained unrestricted research grants from Gilead Sciences, paid to her institute.
Comment on
-
Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study.Lancet HIV. 2023 Apr;10(4):e254-e265. doi: 10.1016/S2352-3018(22)00365-4. Epub 2023 Jan 12. Lancet HIV. 2023. PMID: 36642087 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
